Loading...
ORIC Pharmaceuticals Q1 2025 Earnings Report
ORIC Pharmaceuticals reported its financial results and operational updates for the first quarter of 2025, highlighting progress in clinical development, extended cash runway, and accelerated corporate milestones.
Key Takeaways
ORIC Pharmaceuticals reported a net loss of $30.021 million for the first quarter of 2025, with total assets of $242.858 million and cash and investments of $223.8 million. The company made significant progress in its pipeline, including focused registrational development plans for its lead programs, ORIC-944 and ORIC-114, and extended its cash runway into 2027.
ORIC-944 showed encouraging early safety and efficacy data in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC).
ORIC-114 initiated a clinical trial collaboration with Johnson & Johnson to evaluate its combination with subcutaneous amivantamab for first-line NSCLC.
The company expects five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months.
Cash and investments of approximately $224 million are expected to fund operating plans into 2027.
ORIC Pharmaceuticals
ORIC Pharmaceuticals
Forward Guidance
ORIC Pharmaceuticals anticipates significant clinical data updates and the initiation of registrational trials for its lead programs, ORIC-944 and ORIC-114, over the next 15 months, with current cash and investments expected to fund operations into 2027.
Positive Outlook
- Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months.
- Potential initiation of registrational trials for ORIC-944 in mCRPC in 1H 2026.
- Registrational development of ORIC-114 in first-line NSCLC expected to begin later in 2026.
- Cash and investments of approximately $224 million expected to fund operating plan into 2027.
- Anticipates combination dose escalation data for ORIC-944 with AR inhibitors in 1H 2025 and 2H 2025.
Challenges Ahead
- No specific negative forward guidance was explicitly stated in the provided text.
- Future results could differ materially from projections due to various risks and uncertainties.
- Risks associated with the process of discovering, developing, and commercializing drugs.
- Potential for clinical trials to differ from preclinical, initial, interim, preliminary, or expected results.
- Impacts of health emergencies, economic instability, or international conflicts on operations.